All Articles

A burning question is whether immunotherapy combinations will further improve outcomes over checkpoint inhibitor therapy alone; and if so, which combinations will rise to the top.

Nurse Navigation in Lung Cancer: Original Research Studies

Best Practices in Lung Cancer – November 2018 Vol 9

The following research abstracts in lung cancer were accepted by the Academy of Oncology Nurse & Patient Navigators for the 2018 Annual Conference. We congratulate the authors on their work and the impact they have had on the field of navigation.

Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors

Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series

There is renewed interest in MSI analysis because the MSI-H/dMMR phenotype has emerged as an actionable predictive biomarker for immune checkpoint blockade therapy in different cancer types.

The Importance of MSI/dMMR as Biomarkers in Oncology

Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series

Genotyping tumors for microsatellite instability (MSI) has taken on new importance in the world of oncology. MSI screening has long been recognized as important in the care of patients with colorectal cancer (CRC) or endometrial cancer, and high-level MSI (MSI-H) is now being recognized as a potential marker for germline mutations in certain DNA mismatch-repair (MMR) genes that lead to the development of Lynch syndrome.

Clinical Relevance and Rationale of MSI-H/dMMR as a Biomarker in Patients with Cancer

Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series

Previously, testing for microsatellite instability (MSI) or mismatch repair deficiency (dMMR) has been performed as a screening test to identify patients with Lynch syndrome in colorectal and endometrial cancer, in addition to providing prognostic and predictive data in colorectal cancer (CRC).

Achieving the Mission: Promoting Evidence-Based Navigation Practices

By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG

Letters from Lillie

November 2018 Vol 9, NO 11

This time of year is one of great excitement for us at JONS and the Academy of Oncology Nurse & Patient Navigators (AONN+).

Factors Associated with Adherence to Risk Management for Women with a BRCA Mutation

By Kathryn A. Pratt, BSN, RN, OCN, CBCN; Jillian Huang, MS, MPH, CGC

AONN+ Conference Abstracts, Community Outreach and Prevention

November 2018 Vol 9, NO 11

Individuals with hereditary breast and ovarian cancer syndrome (HBOC), caused by mutations in BRCA1 and BRCA2, have some of the highest cancer incidences of any known group.

Liver Fluke and Cholangiocarcinoma: Navigators Can Advocate for Early Screening

By Jolene Hetsler, RN, ONS; Sania Richards, RN, BSN, ONS

AONN+ Conference Abstracts, Community Outreach and Prevention

November 2018 Vol 9, NO 11

Travel and global military presence dictate that international diseases can affect the American populace.

Testing Telephone-Based Patient Navigation for Lung Cancer Screening in an Integrated Safety Net System

By Simon Craddock Lee, PhD, MPH; Heidi A. Hamann, PhD; Magalis Z. Tijerina, BA; Cynthia Ortiz, MPH; Claudia Chavez, MBA; Noel Santini, MD; David E. Gerber, MD

AONN+ Conference Abstracts, Community Outreach and Prevention

November 2018 Vol 9, NO 11

While adherence to annual screening exceeded 90% in the National Lung Screening Trial, the trial population was disproportionately white, educated, and received care in the tightly controlled environment of a clinical trial.

The Importance of Nurse Navigation in Lung Cancer Screening

By Stephanie M. Hoopes, BSN, RN, OCN, ONN-CG; Gina Franco, MSN, ANP-C; Jo Weathers, RN, BSN, OCN, CBCN; Pamela Cloys, MSN, ANP-C; LeAnn Perkins, FNP-BC, DipACLM; Mark A O'Rourke, MD; Patricia Leighton, MSN Ed, OCN, ONN-CG

AONN+ Conference Abstracts, Community Outreach and Prevention

November 2018 Vol 9, NO 11

Lung cancer is the leading cause of cancerrelated death for men and women in the United States.

All Articles

Page 188 of 283

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.